Drug Type Biological products |
Synonyms OMO 103, OMO-103, OMO103 |
Target |
Mechanism MYC inhibitors(Myc proto-oncogene protein inhibitors) |
Inactive Indication |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Start Date31 Aug 2023 |
Sponsor / Collaborator ![]() |
Start Date28 Apr 2021 |
Sponsor / Collaborator ![]() |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | ES | Peptomyc SLStartup | 28 Apr 2021 |
Colorectal Cancer | Phase 2 | ES | Peptomyc SLStartup | 28 Apr 2021 |
Pancreatic Cancer | Phase 2 | ES | Peptomyc SLStartup | 28 Apr 2021 |
Pancreatic Ductal Adenocarcinoma | Phase 1 | ES | Peptomyc SLStartup | 31 Aug 2023 |
Secondary malignant neoplasm of pancreas | Phase 1 | ES | Peptomyc SLStartup | 31 Aug 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 22 | lfbgwdskpz(upxvsyputt) = yiirrurgzt hehtovqsqr (hkgwrhmydn, dsopuickxw - ymnkkyjivk) View more | - | 25 Apr 2024 | |||
Phase 1 | Solid tumor MYC | 22 | dugddzabpt(vjzsotapfp) = dolraoqjez kzsvsekeld (caegtqjubm ) View more | Positive | 01 Mar 2024 | ||
NCT04808362 (ENA2022) Manual | Phase 1 | 22 | dftmnlhzzt(zkpcnbnewo) = kugtdioytr oramjkxitu (ljdvicdhau ) View more | Positive | 01 Nov 2022 |